Michael Loberg, PhD, Chairman
Dr. Loberg also serves on the board of directors of ArQule, a biopharmaceutical company, and is also a member of its compensation, nominating and governance committee and science committee. Dr. Loberg previously held a number of senior management positions at Bristol-Myers Squibb, including President of Bristol-Myers Squibb’s Oncology and Immunology, U.S. Primary Care, Northern Europe, Specialty Pharmaceuticals and Squibb Diagnostics divisions, as well as Director and Vice President, E.R. Squibb & Sons Research and Development. Dr. Loberg also previously served on the board of directors and as Interim Chief Executive Officer of Inotek Pharmaceuticals and as Chief Executive Officer and a member of the Board of Directors of NitroMed. Dr. Loberg received a B.S. in Chemistry from Trinity College and a Ph.D. in Chemistry from Washington University in St. Louis.
M. Kathleen Behrens, PhD
Dr. Behrens also serves as a member and chair of the board of directors of Sarepta Therapeutics, a medical research and drug development company, as well as chair of its audit committee and a member of its research and development committee. She is also a member and chair of the board of MiMedx Group, a wound care company, as well as a member of its compliance and ethics committee. Dr. Behrens served on the board of directors of Amylin Pharmaceuticals, a biotechnology company, from June 2009 until its sale to Bristol-Myers Squibb in 2012. From 1996 to December 2009, Dr. Behrens served in various roles at RS Investments, an investment management and research firm, including as a general partner for selected venture funds. From 1983 to 1996, she served as a general partner and managing director at Robertson Stephens & Co. She served as a member of the President’s Council of Advisors on Science and Technology (PCAST) from 2001 to early 2009 and as chairwoman of its subcommittee on Personalized Medicine. She also served on the Board on Science, Technology and Economic Policy for the National Research Council and as a Director, President and Chairwoman of the National Venture Capital Association. Dr. Behrens received a B.S. in Biological Sciences and a Ph.D. in Microbiology from the University of California, Davis.
Julie Hambleton, MD
Dr. Hambleton also serves as senior vice president, chief medical officer, head of development at IDEAYA Biosciences, an oncology medicine company. Previously, she served as vice president, head U.S. Medical at Bristol-Myers Squibb. She also previously served as executive vice president, chief medical officer at Five Prime Therapeutics, a biotechnology company. Previously, she served as vice president, clinical development at Clovis Oncology, a biotechnology company. Previously, Dr. Hambleton held increasing roles of responsibility in BioOncology at Roche/Genentech. Dr. Hambleton completed her hematology-oncology training at the University of California, San Francisco, and she served on the faculty there from 1993 to 2003. Dr. Hambleton received a B.S. in Nursing from Duke University and an M.D. from Case Western Reserve University School of Medicine, and she is board-certified in Hematology and Internal Medicine.
Mr. Lee is a co-founder and portfolio manager at Redmile Group, LLC, a health care-focused investment firm based in San Francisco and New York. Prior to Redmile, he worked as a biotechnology investor at Steeple Capital, and before that at Welch Capital Partners and Prudential Equity Group. Mike holds a B.S. in Molecular and Cellular Biology from the University of Arizona.
Kelvin M. Neu, MD
Dr. Neu is a Managing Director of Baker Brothers Investments. Dr. Neu holds an M.D. from the Harvard Medical School-MIT Health Sciences and Technology program, and he spent three years in the Immunology Ph.D. program at Stanford University as a Howard Hughes Medical Institute Fellow.
Fred M. Schwarzer
Mr. Schwarzer has served as our chief executive officer and a member of our board since 2010. Mr. Schwarzer also served as a managing partner of Charter Life Sciences, a venture capital firm specializing in life sciences investments, for approximately 15 years. He also served as the chair of Inviragen, the creators of the DENVax dengue vaccine, from the time of its first venture capital financing until its acquisition by Takeda. He previously served as chief executive officer and then chair of the board of directors of Heska Corporation, a biotechnology company. Mr. Schwarzer received a B.A. in Pre-Legal Studies from the University of Michigan and a J.D. from the University of California, Berkeley, School of Law.
William Strohl, PhD
Dr. Strohl is the founder and president of BiStro Biotech Consulting, a biotechnology consulting company. Previously, Dr. Strohl served as vice president and biologics fellow at Janssen BioTherapeutics, the therapeutic biologics organization within the Janssen Research & Development division of Johnson & Johnson, and he served as its vice president and head from October 2013 to February 2016. Prior to that, Dr. Strohl served as Head of Antibody Discovery at Janssen BioTherapeutics. Dr. Strohl also held various roles at Merck, including leading Natural Products Biology and leading Biologics discovery efforts. Previously, he was a Professor in the Department of Microbiology and the Program of Biochemistry at The Ohio State University. Dr. Strohl received a B.S. in Biology from Central Michigan University and a Ph.D. in Microbiology from Louisiana State University.
Christina Teng Topsøe
Ms. Topsøe serves on the board of directors of Haldor Topsøe, and Haldor Topsøe Holding, its holding company. Ms. Topsøe previously served as a lawyer at Allen & Overy LLP and Simpson Thacher and Bartlett LLP. Ms. Topsøe received an LL.B. from the University of London and an M.B.A. from London Business School and Columbia Business School.
Jakob Haldor Topsøe
Mr. Topsøe as is the vice chair of Haldor Topsøe and chair of Haldor Topsøe Holding, its holding company. Mr. Topsøe previously served as partner at AMBROX Capital, a Danish investment management firm. Mr. Topsøe has also served in various functions within Alfred Berg/ABN Amro Bank including Head of Equities, Denmark. Mr. Topsøe also currently serves as a member of the board of directors of Motortramp, a Danish provider of marine transportation services, and Dampskibsselskabet Orients Fond, a Danish charitable foundation. Mr. Topsøe received an H.D. in Finance from the Copenhagen Business School.